663 related articles for article (PubMed ID: 23075643)
1. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Ding WY; Lee CK; Choon SE
Int J Dermatol; 2010 Jul; 49(7):834-41. PubMed ID: 20618508
[TBL] [Abstract][Full Text] [Related]
3. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
Tan SK; Tay YK
Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of cutaneous adverse drug reactions.
Mockenhaupt M
Chem Immunol Allergy; 2012; 97():1-17. PubMed ID: 22613850
[TBL] [Abstract][Full Text] [Related]
5. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
Loo CH; Tan WC; Khor YH; Chan LC
Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China.
Li LF; Ma C
Clin Exp Dermatol; 2006 Sep; 31(5):642-7. PubMed ID: 16901302
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
[TBL] [Abstract][Full Text] [Related]
8. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
9. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse drug reactions: an 8-year retrospective study on hospitalized patients in Southern China.
Wang F; Li Y; Mo Y; Shen C; Yang L; Zhang X
Indian J Dermatol Venereol Leprol; 2012; 78(4):488-90. PubMed ID: 22772622
[No Abstract] [Full Text] [Related]
11. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
12. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
13. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.
Chan HL; Stern RS; Arndt KA; Langlois J; Jick SS; Jick H; Walker AM
Arch Dermatol; 1990 Jan; 126(1):43-7. PubMed ID: 2404462
[TBL] [Abstract][Full Text] [Related]
14. Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017.
Kim HK; Kim DY; Bae EK; Kim DW
J Korean Med Sci; 2020 Feb; 35(4):e17. PubMed ID: 31997613
[TBL] [Abstract][Full Text] [Related]
15. Incidence of cutaneous adverse drug reactions among medical inpatients of Sultanah Aminah Hospital Johor Bahru.
Latha S; Choon SE
Med J Malaysia; 2017 Jun; 72(3):151-156. PubMed ID: 28733562
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous drug reactions in patients admitted to the dermatology unit at the University Hospital of the West Indies, Kingston, Jamaica.
East-Innis AD; Thompson DS
West Indian Med J; 2009 Jun; 58(3):227-30. PubMed ID: 20043529
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous adverse drug reactions: clinical pattern and causative agents--a 6 year series from Chandigarh, India.
Sharma VK; Sethuraman G; Kumar B
J Postgrad Med; 2001; 47(2):95-9. PubMed ID: 11832597
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and prognostic factors in severe cutaneous drug reactions.
Yang MS; Kang MG; Jung JW; Song WJ; Kang HR; Cho SH; Min KU
Int Arch Allergy Immunol; 2013; 162(4):346-54. PubMed ID: 24193402
[TBL] [Abstract][Full Text] [Related]
19. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS.
Viera MH; Perez OA; Patel JK; Jones I; Berman B
Cutis; 2010 Jun; 85(6):312-7. PubMed ID: 20666193
[TBL] [Abstract][Full Text] [Related]
20. [Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia].
Gamba C; Schroeder J; Citterio A; Cazzaniga S; Rivolta AL; Vighi G;
Recenti Prog Med; 2014 Oct; 105(10):379-84. PubMed ID: 25282350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
